Published on 9 Aug 2022 on Zacks via Yahoo Finance

Can Amryt Pharma PLC Sponsored ADR (AMYT) Climb 187% to Reach the Level Wall Street Analysts Expect?

Amryt Pharma PLC Sponsored ADR (AMYT) closed the last trading session at $7.87, gaining 11.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $22.60 indicates an 187.2% upside potential.

The average comprises five short-term price targets ranging from a low of $18 to a high of $33, with a standard deviation of $6.50. While the lowest estimate indicates an increase of 128.7% from the current price level, the most optimistic estimate points to a 319.3% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.

While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.